SciClone Pharmaceuticals, Inc. reconfirmed earnings guidance for the year 2014 and provided sales revenue guidance for the year 2015. For the year 2014, the company reconfirmed expected sales revenue of $130 million to $135 million, representing an approximate 30% increase of its core business revenue over 2013. The company reconfirmed non-GAAP EPS of $0.64 to $0.68, as a result of reduced marketing and general and administrative expenses.

For the year 2015, the company anticipates sales revenue of $153 million to $158 million, representing an approximately 17% increase over 2014.